BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tivozanib: Phase Ib data

Data from 17 evaluable patients in an open-label, dose-escalation Phase Ib trial showed that once-daily oral tivozanib plus FOLFOX6 (5-FU, leucovorin, and oxaliplatin) chemotherapy produced 6 partial responses, including 1 patient who experienced tumor shrinkage of >50%, and 8 cases of stable disease. DLTs included 1 case of...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >